Stay updated on Pembrolizumab in MM Residual Disease Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.

Latest updates to the Pembrolizumab in MM Residual Disease Clinical Trial page
- Check7 days agoChange DetectedPage revision updated from v3.6.4 to v3.6.5, representing a minor version bump. This update aligns with backend or template changes rather than a modification to the study content.SummaryDifference0.1%

- Check14 days agoChange DetectedThe page's disease label 'Multiple myeloma' and the related topics section, including the MedlinePlus Genetics link, were removed, reducing disease-specific context and cross-references.SummaryDifference0.2%

- Check21 days agoChange DetectedThe page's revision label was updated from v3.6.3 to v3.6.4, indicating a backend/platform update. This change does not alter the study content, eligibility criteria, or results.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedPage revision tag updated from v3.6.2 to v3.6.3. This represents a small update to the page metadata and does not alter displayed study details.SummaryDifference0.1%

- Check49 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a backend update to the page. This does not alter study details or visible content.SummaryDifference0.1%

- Check64 days agoChange DetectedNew study-record navigation items have been added (How to Read a Study Record, Common Questions, How to Join a Study), and the Intervention/Treatment heading has been standardized. A banner now shows No longer looking for participants, and the revision/version is updated to v3.6.0, replacing the previous v3.5.5.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab in MM Residual Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.